Ascertaining Longterm Outcomes of Fibroid Treatments
Launched by HENRY FORD HEALTH SYSTEM · May 21, 2024
Trial Information
Current as of March 13, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Participant has to have been enrolled in either the COMPARE-UF or ULTRA study
- • Participant had a uterine-sparing fibroid treatment at enrollment in COMPARE-UF or ULTRA study
- Exclusion Criteria:
- • Individuals who were not consented into the original COMPARE-UF or ULTRA study
- • Individuals who did not have a uterine-sparing fibroid treatment at enrollment in COMPARE-UF or ULTRA study
Trial Officials
Ganesa Wegienka, PhD
Principal Investigator
Henry Ford Health
About Henry Ford Health System
Henry Ford Health System is a comprehensive, nonprofit healthcare organization based in Detroit, Michigan, renowned for its commitment to advancing medical research and patient care. With a robust network of hospitals, outpatient facilities, and specialty clinics, Henry Ford Health System is dedicated to innovation in clinical trials, focusing on translating scientific discoveries into effective treatments. The organization emphasizes multidisciplinary collaboration, leveraging its extensive resources and expertise to address diverse health challenges. Through its clinical research initiatives, Henry Ford Health System aims to enhance patient outcomes and contribute to the advancement of medical knowledge on both a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
San Francisco, California, United States
Chapel Hill, North Carolina, United States
Detroit, Michigan, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
